PriceTargets.com logo

Terns Pharmaceuticals - TERN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $16.11
  • Forecasted Upside: 239.90%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$4.74 As of 09/28/2023 01:36 PM ET
▼ -0.06 (-1.25%)

This chart shows the closing price for TERN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Terns Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TERN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TERN

Analyst Price Target is $16.11
▲ +239.90% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Terns Pharmaceuticals in the last 3 months. The average price target is $16.11, with a high forecast of $23.00 and a low forecast of $8.00. The average price target represents a 239.90% upside from the last price of $4.74.

This chart shows the closing price for TERN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Terns Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$10.00 ➝ $11.00N/A
8/9/2023HC WainwrightLower TargetNeutral ➝ Neutral$11.00 ➝ $8.00Low
8/9/2023MizuhoBoost Target$16.00 ➝ $17.00Low
8/8/2023Roth MkmReiterated RatingBuy$23.00Low
6/30/2023MizuhoReiterated RatingBuy ➝ Buy$16.00Low
6/30/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$17.00Low
6/30/2023Roth MkmReiterated RatingBuy ➝ Buy$23.00Low
6/22/2023MizuhoInitiated CoverageBuy$16.00Low
6/7/2023Jefferies Financial GroupInitiated CoverageBuy$18.00Low
5/31/2023Roth MkmInitiated CoverageBuy$23.00Low
5/8/2023BMO Capital MarketsInitiated CoverageOutperform$18.00Low
3/29/2023JPMorgan Chase & Co.Boost TargetNeutral$6.00 ➝ $9.00Low
3/29/2023JMP SecuritiesReiterated RatingMarket Outperform$17.00Low
3/29/2023HC WainwrightBoost TargetNeutral$7.00 ➝ $11.00Low
2/14/2023JMP SecuritiesInitiated CoverageOutperform$17.00Low
2/7/2023UBS GroupInitiated CoverageBuy$19.00Low
12/29/2022HC WainwrightBoost TargetNeutral$6.00 ➝ $7.00Low
12/20/2022The Goldman Sachs GroupBoost TargetBuy$9.00 ➝ $14.00Low
9/27/2022The Goldman Sachs GroupBoost TargetBuy$4.00 ➝ $9.00Low
9/12/2022HC WainwrightInitiated CoverageNeutral$6.00Low
3/23/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00 ➝ $6.00High
9/14/2021The Goldman Sachs GroupInitiated CoverageBuy$21.00High
3/2/2021JPMorgan Chase & Co.Initiated CoverageOverweight$32.00High
3/2/2021CowenInitiated CoverageOutperformHigh
3/2/2021The Goldman Sachs GroupInitiated CoverageBuy$29.00Medium
(Data available from 9/28/2018 forward)

News Sentiment Rating

1.03 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2023
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2023
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2023
  • 5 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Terns Pharmaceuticals logo
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $4.74
Low: $4.60
High: $4.93

50 Day Range

MA: $5.94
Low: $4.80
High: $8.03

52 Week Range

Now: $4.74
Low: $4.38
High: $14.04

Volume

77,375 shs

Average Volume

561,769 shs

Market Capitalization

$289.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Terns Pharmaceuticals?

The following Wall Street analysts have issued reports on Terns Pharmaceuticals in the last twelve months: BMO Capital Markets, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Mizuho, Roth Mkm, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for TERN.

What is the current price target for Terns Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Terns Pharmaceuticals in the last year. Their average twelve-month price target is $16.11, suggesting a possible upside of 239.9%. Roth Mkm has the highest price target set, predicting TERN will reach $23.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Terns Pharmaceuticals in the next year.
View the latest price targets for TERN.

What is the current consensus analyst rating for Terns Pharmaceuticals?

Terns Pharmaceuticals currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TERN.

What other companies compete with Terns Pharmaceuticals?

Other companies that are similar to Terns Pharmaceuticals include Nature's Sunshine Products, Nuvation Bio, Erasca, Arbutus Biopharma and Seres Therapeutics. Learn More about companies similar to Terns Pharmaceuticals.

How do I contact Terns Pharmaceuticals' investor relations team?

Terns Pharmaceuticals' physical mailing address is 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404. The company's listed phone number is 650-525-5535 and its investor relations email address is [email protected]. The official website for Terns Pharmaceuticals is www.ternspharma.com. Learn More about contacing Terns Pharmaceuticals investor relations.